Durect Revenue Growth Rates (DRRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Durect Corp  (NASDAQ: DRRX)
 

DRRX's Revenue Growth by Quarter and Year

Durect's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DRRX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.45
1st Quarter March 0.32
FY 0.77

DRRXs Annual Revenue
Durect's Revenue in the fiscal year 2024 $ 2.03 millions
Durect's Revenue in the fiscal year 2023 $ 8.55 millions
Durect's Revenue in the fiscal year 2022 $ 19.28 millions
Durect's Revenue in the fiscal year 2021 $ 13.98 millions
Durect's Revenue in the fiscal year 2020 $ 30.11 millions




DRRX Revenue second quarter 2025 Y/Y Growth Comment
Durect Corp reported drop in Revenue in the second quarter 2025 by -79.4% to $ 0.45 millions, from the same quarter in 2024.
The fall in the second quarter 2025 Durect Corp's Revenue compares unfavorably to the Company's average Revenue rise of 28.89%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Revenue growth. While Durect Corp' s Revenue meltdown of -79.4% ranks overall at the positon no. 3502 in the second quarter 2025.


DRRX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - - -19.58 % -54.52 %
3rd Quarter September - 10.92 % -85.48 % 452.07 %
2nd Quarter June -79.4 % 4.33 % 0 % -9.57 %
1st Quarter March -82.51 % -10.73 % 6.77 % -13.12 %
FY   - -30.56 % -55.75 % -

Financial Statements
Durect's second quarter 2025 Revenue $ 0.45 millions DRRX's Income Statement
Durect's second quarter 2024 Revenue $ 2.17 millions Quarterly DRRX's Income Statement


DRRX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - 53.45 % -72.29 %
3rd Quarter September - -11.06 % -16.35 % 475.96 %
2nd Quarter June 39.69 % 18.58 % 1.46 % 8.33 %
1st Quarter March - -31.46 % -38.25 % -73.7 %
FY (Year on Year)   - -30.56 % -55.75 % -


Back to DRRX Growth rate Comparisons >> Back to DRRX Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #180
Healthcare Sector #508
Overall #3502

Revenue Y/Y Growth Statistics
High Average Low
548.53 % 28.89 % -100 %
(Sep 30 2022)   (Jun 30 2021)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #180
Healthcare Sector #508
Overall #3502
Revenue Y/Y Growth Statistics
High Average Low
548.53 % 28.89 % -100 %
(Sep 30 2022)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Durect's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
831.32 % 34.01 % -100 %
(Jun 30 2020)  


DRRX's II. Quarter Q/Q Revenue Comment
Durect Corp achieved in the II. Quarter 2025 above company average sequential Revenue jump of 39.69%, to $ 0.45 millions, from $0.32 millions in the first quarter.
DRRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Durect's Revenue growth quarter on quarter, overall rank is 246.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #70
Overall #246
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #70
Overall #246
Revenue Q/Q Growth Statistics
High Average Low
831.32 % 34.01 % -100 %
(Jun 30 2020)  


DRRX's II. Quarter Q/Q Revenue Comment
Durect Corp achieved in the II. Quarter 2025 above company average sequential Revenue jump of 39.69%, to $ 0.45 millions, from $0.32 millions in the first quarter.
DRRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Durect's Revenue growth quarter on quarter, overall rank is 246.


Durect's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 8.59 $ 8.41
Y / Y Revenue Growth (TTM) - - - -6.53 % -56.7 %
Year on Year Revenue Growth Overall Ranking # 2900 # 2805 # 3195 # 3028 # 270
Seqeuential Revenue Change (TTM) - - - 2.18 % 1.08 %
Seq. Revenue Growth (TTM) Overall Ranking # 1805 # 2036 # 2562 # 3009 # 1917


Cumulative Revenue growth Comment
Durect Corp realized trailing twelve months of $ 0 millions, in the Jun 30 2025, compare to Revenue of $ 8 millions a year ago.

In the Healthcare sector 417 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2805 to 2900.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 418
Overall # 2900

Revenue TTM Y/Y Growth Statistics
High Average Low
323.85 %
 21.67 %
-88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 88
Sector # 277
S&P 500 # 1805
Cumulative Revenue growth Comment
Durect Corp realized trailing twelve months of $ 0 millions, in the Jun 30 2025, compare to Revenue of $ 8 millions a year ago.

In the Healthcare sector 417 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2805 to 2900.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 418
Overall # 2900

Revenue TTM Y/Y Growth Statistics
High Average Low
323.85 %
21.67 %
-88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 88
Sector # 277
S&P 500 # 1805




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DRRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Carlisle Companies Incorporated-0.08%$ -0.076 millions
Zimvie Inc -0.13%$ -0.128 millions
Community Health Systems Inc -0.22%$ -0.223 millions
Bruker Corporation-0.46%$ -0.462 millions
Integra Lifesciences Holdings Corp-0.61%$ -0.615 millions
Adapthealth Corp -0.70%$ -0.695 millions
Perrigo Company Plc-0.79%$ -0.789 millions
Organon and Co -0.81%$ -0.809 millions
Castle Biosciences Inc -0.94%$ -0.936 millions
Vaso Corporation-0.96%$ -0.963 millions
Profound Medical Corp -0.99%$ -0.985 millions
Capsovision Inc -1.13%$ -1.126 millions
Avantor Inc -1.14%$ -1.139 millions
Inspiremd Inc -1.35%$ -1.352 millions
Align Technology inc -1.51%$ -1.509 millions
Teladoc Health Inc -1.64%$ -1.641 millions
Supernus Pharmaceuticals inc -1.71%$ -1.706 millions
Encision Inc -1.73%$ -1.729 millions
Cytek Biosciences Inc -1.80%$ -1.796 millions
Merck and Co Inc -1.90%$ -1.899 millions
Bioventus Inc -1.98%$ -1.978 millions
Alkermes Plc -2.12%$ -2.123 millions
Anteris Technologies Global Corp -2.22%$ -2.215 millions
Surmodics Inc -2.55%$ -2.551 millions
Nrc Health-2.81%$ -2.807 millions
Rxsight Inc -3.09%$ -3.095 millions
Apyx Medical Corp-3.57%$ -3.567 millions
Quidelortho Corp-3.63%$ -3.626 millions
Lantheus Holdings Inc -4.00%$ -4.003 millions
Quipt Home Medical Corp -4.07%$ -4.065 millions


About Durect Revenue Growth Rates (DRRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Durect Corp (CIK 1082038).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-25-108150
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Durect Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.